Cargando…
Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors
BACKGROUND AND AIMS: Sexual dysfunctions (SDs) show a marked impact on a person’s general wellbeing. Several risk-factors like physical and mental illnesses as well as alcohol and tobacco use have to date been identified to contribute to the occurrence of SDs. The impact of opioid-agonist treatment...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980546/ https://www.ncbi.nlm.nih.gov/pubmed/35392381 http://dx.doi.org/10.3389/fpsyt.2022.846834 |
_version_ | 1784681418998153216 |
---|---|
author | Meyer, Maximilian Brunner, Patrick Geissmann, Leonie Gürtler, Martin Schwager, Fabienne Waldis, Rowena Vogel, Marc Wiesbeck, Gerhard A. Dürsteler, Kenneth M. |
author_facet | Meyer, Maximilian Brunner, Patrick Geissmann, Leonie Gürtler, Martin Schwager, Fabienne Waldis, Rowena Vogel, Marc Wiesbeck, Gerhard A. Dürsteler, Kenneth M. |
author_sort | Meyer, Maximilian |
collection | PubMed |
description | BACKGROUND AND AIMS: Sexual dysfunctions (SDs) show a marked impact on a person’s general wellbeing. Several risk-factors like physical and mental illnesses as well as alcohol and tobacco use have to date been identified to contribute to the occurrence of SDs. The impact of opioid-agonist treatment (OAT) on SDs remains unclear, with some studies demonstrating an improvement after methadone maintenance treatment (MMT) initiation. However, no studies on the prevalence and predictors of SDs in heroin-assisted treatment (HAT) exist to date. METHODS: A cross-sectional study was conducted with patients from a MMT center (n = 57) and a center specializing in HAT (n = 47). A control group of patients with mild transient illnesses (n = 67) was recruited from a general practitioner (GP). The International Index of Erectile Function, the Female Sexual Function Index, as well as measurements for psychological distress, depressive state, nicotine dependence, and high-risk alcohol use were employed. Patients also completed a self-designed questionnaire on help-seeking behavior regarding sexual health. Mann-Whitney-U tests and chi-square tests were performed for group comparisons and binary logistic regression models were calculated. RESULTS: Twenty-five percent of the GP sample (n = 17), 70.2% (n = 40) of the MMT sample, and 57.4% (n = 27) of the HAT sample suffered from SDs at the time of study conduction. OAT patients differed significantly from GP patients in depressive state, high-risk alcohol use, nicotine dependence, and psychological distress. Age, depressive state, and opioid dependence predicted the occurrence of SDs in the total sample. No differences between OAT and GP patients were found regarding help-seeking behavior. DISCUSSION: Age, depressive state, and opioid dependence predicted the occurrence of SDs in the total sample. It remains unclear whether SDs are caused by opioid intake itself or result from other substance-use related lifestyle factors, that were not controlled for in this study. A lack of help-seeking behavior was observed in our sample, underlining the importance of clinicians proactively inquiring about the sexual health of their patients. CONCLUSION: The high prevalence of SDs observed in MMT does not differ from the prevalence in HAT. Clinicians should actively inquire about their patients’ sexual health in GP and OAT centers alike. |
format | Online Article Text |
id | pubmed-8980546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89805462022-04-06 Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors Meyer, Maximilian Brunner, Patrick Geissmann, Leonie Gürtler, Martin Schwager, Fabienne Waldis, Rowena Vogel, Marc Wiesbeck, Gerhard A. Dürsteler, Kenneth M. Front Psychiatry Psychiatry BACKGROUND AND AIMS: Sexual dysfunctions (SDs) show a marked impact on a person’s general wellbeing. Several risk-factors like physical and mental illnesses as well as alcohol and tobacco use have to date been identified to contribute to the occurrence of SDs. The impact of opioid-agonist treatment (OAT) on SDs remains unclear, with some studies demonstrating an improvement after methadone maintenance treatment (MMT) initiation. However, no studies on the prevalence and predictors of SDs in heroin-assisted treatment (HAT) exist to date. METHODS: A cross-sectional study was conducted with patients from a MMT center (n = 57) and a center specializing in HAT (n = 47). A control group of patients with mild transient illnesses (n = 67) was recruited from a general practitioner (GP). The International Index of Erectile Function, the Female Sexual Function Index, as well as measurements for psychological distress, depressive state, nicotine dependence, and high-risk alcohol use were employed. Patients also completed a self-designed questionnaire on help-seeking behavior regarding sexual health. Mann-Whitney-U tests and chi-square tests were performed for group comparisons and binary logistic regression models were calculated. RESULTS: Twenty-five percent of the GP sample (n = 17), 70.2% (n = 40) of the MMT sample, and 57.4% (n = 27) of the HAT sample suffered from SDs at the time of study conduction. OAT patients differed significantly from GP patients in depressive state, high-risk alcohol use, nicotine dependence, and psychological distress. Age, depressive state, and opioid dependence predicted the occurrence of SDs in the total sample. No differences between OAT and GP patients were found regarding help-seeking behavior. DISCUSSION: Age, depressive state, and opioid dependence predicted the occurrence of SDs in the total sample. It remains unclear whether SDs are caused by opioid intake itself or result from other substance-use related lifestyle factors, that were not controlled for in this study. A lack of help-seeking behavior was observed in our sample, underlining the importance of clinicians proactively inquiring about the sexual health of their patients. CONCLUSION: The high prevalence of SDs observed in MMT does not differ from the prevalence in HAT. Clinicians should actively inquire about their patients’ sexual health in GP and OAT centers alike. Frontiers Media S.A. 2022-03-22 /pmc/articles/PMC8980546/ /pubmed/35392381 http://dx.doi.org/10.3389/fpsyt.2022.846834 Text en Copyright © 2022 Meyer, Brunner, Geissmann, Gürtler, Schwager, Waldis, Vogel, Wiesbeck and Dürsteler. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Meyer, Maximilian Brunner, Patrick Geissmann, Leonie Gürtler, Martin Schwager, Fabienne Waldis, Rowena Vogel, Marc Wiesbeck, Gerhard A. Dürsteler, Kenneth M. Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors |
title | Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors |
title_full | Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors |
title_fullStr | Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors |
title_full_unstemmed | Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors |
title_short | Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors |
title_sort | sexual dysfunctions in patients receiving opioid agonist treatment and heroin-assisted treatment compared to patients in private practice—identifying group differences and predictors |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980546/ https://www.ncbi.nlm.nih.gov/pubmed/35392381 http://dx.doi.org/10.3389/fpsyt.2022.846834 |
work_keys_str_mv | AT meyermaximilian sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors AT brunnerpatrick sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors AT geissmannleonie sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors AT gurtlermartin sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors AT schwagerfabienne sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors AT waldisrowena sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors AT vogelmarc sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors AT wiesbeckgerharda sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors AT durstelerkennethm sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors |